These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9741326)

  • 1. Morphology of bone metastasis.
    Hiraga T; Tanaka S; Ikegame M; Koizumi M; Iguchi H; Nakajima T; Ozawa H
    Eur J Cancer; 1998 Feb; 34(2):230-9. PubMed ID: 9741326
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of bisphosphonate (pamidronate) on bone resorption resulting from metastasis of a squamous cell carcinoma: report of an autopsy case and evaluation of bone resorbing activity in an experimental animal model.
    Hiraga T; Takada M; Nakajima T; Ozawa H
    J Oral Maxillofac Surg; 1996 Nov; 54(11):1327-33. PubMed ID: 8941184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Establishment of a model to evaluate inhibition of bone resorption induced by bladder tumor (MBT-2) in mice].
    Nishijima Y; Nemoto R; Koiso K
    Nihon Hinyokika Gakkai Zasshi; 1990 May; 81(5):694-700. PubMed ID: 2376925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revisiting the seed and soil theory of bone metastasis: new tools, same answer.
    Kostenuik PJ
    J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):375-6. PubMed ID: 15758267
    [No Abstract]   [Full Text] [Related]  

  • 5. Ammonium tetrathiomolybdate enhances the antitumor effects of cetuximab via the suppression of osteoclastogenesis in head and neck squamous carcinoma.
    Morisawa A; Okui T; Shimo T; Ibaragi S; Okusha Y; Ono M; Nguyen TTH; Hassan NMM; Sasaki A
    Int J Oncol; 2018 Mar; 52(3):989-999. PubMed ID: 29328370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of different osteoclast phenotypes in the progression of bone invasion by oral squamous cell carcinoma.
    Quan J; Hou Y; Long W; Ye S; Wang Z
    Oncol Rep; 2018 Mar; 39(3):1043-1051. PubMed ID: 29286135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
    Jobke B; Milovanovic P; Amling M; Busse B
    Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases.
    Schem C; Tower RJ; Kneissl P; Rambow AC; Campbell GM; Desel C; Damm T; Heilmann T; Fuchs S; Zuhayra M; Trauzold A; Glüer CC; Schott S; Tiwari S
    J Bone Miner Res; 2017 Mar; 32(3):536-548. PubMed ID: 27714838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronate in the treatment of osteolytic bone metastases.
    Lipton A
    Br J Clin Pract Suppl; 1996 Sep; 87():21; discussion 22. PubMed ID: 8995015
    [No Abstract]   [Full Text] [Related]  

  • 10. Diphosphonates for osteolytic metastases.
    Elomaa I; Blomqvist C; Porkka L; Holmström T; Taube T; Lamberg-Allardt C; Borgström GH
    Lancet; 1985 May; 1(8438):1155-6. PubMed ID: 2860356
    [No Abstract]   [Full Text] [Related]  

  • 11. Emerging therapies in bone metastasis.
    Clément-Demange L; Clézardin P
    Curr Opin Pharmacol; 2015 Jun; 22():79-86. PubMed ID: 25935860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pamidronate decreases tumor-induced osteoclastogenesis in osteopetrotic mice.
    Clohisy DR; O' Keefe PF; Ramnaraine ML
    J Orthop Res; 2001 Jul; 19(4):554-8. PubMed ID: 11518261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bone hyperresorption in bone metastases].
    Clézardin P
    Presse Med; 2000 Mar; 29(9):487-91. PubMed ID: 10745942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular basis of bone metastasis formation and its targeted therapy].
    Tímár J
    Magy Onkol; 2010 Mar; 54(1):59-64. PubMed ID: 20350869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathophysiology of bone metastases in urologic carcinomas].
    Sauer G; Barth TF; Möller P
    Urologe A; 2007 Aug; 46(8):888-90. PubMed ID: 17632696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pamidronate in the treatment of osteolytic bone metastases in breast cancer patients.
    Theriault R
    Br J Clin Pract Suppl; 1996 Sep; 87():8-12; discussion 13-4. PubMed ID: 8995011
    [No Abstract]   [Full Text] [Related]  

  • 17. Metastatic bone disease and the role of bisphosphonates.
    Ellis MJ
    Br J Hosp Med; 1996 Oct 2-15; 56(7):339-45. PubMed ID: 8899222
    [No Abstract]   [Full Text] [Related]  

  • 18. Pamidronate in the treatment of bone metastases--the European experience.
    Ford JF
    Br J Clin Pract Suppl; 1996 Sep; 87():3-4; discussion 13-4. PubMed ID: 8995009
    [No Abstract]   [Full Text] [Related]  

  • 19. Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss.
    Rucci N; Capulli M; Ventura L; Angelucci A; Peruzzi B; Tillgren V; Muraca M; Heinegård D; Teti A
    J Bone Miner Res; 2013 Sep; 28(9):1912-24. PubMed ID: 23559035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bisphosphonates and bone metastases of solid tumors: therapeutic interest despite its anti-resorptive properties].
    Clézardin P
    Prog Urol; 2003 Apr; 13(2 Suppl 1):28-35. PubMed ID: 12815807
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.